Navigation Links
Sanford-Burnham researchers develop novel nanoparticle to deliver powerful RNA interference drugs
Date:7/9/2013

LA JOLLA, Calif., July 8 2013 Silencing genes that have malfunctioned is an important approach for treating diseases such as cancer and heart disease. One effective approach is to deliver drugs made from small molecules of ribonucleic acid, or RNA, which are used to inhibit gene expression. The drugs, in essence, mimic a natural process called RNA interference.

In a new paper appearing today online in the journal, ACS Medicinal Chemistry Letters, researchers at Sanford-Burnham Medical Research Institute have developed nanoparticles that appear to solve a big challenge in delivering the RNA molecules, called small interfering RNA, or siRNA, to the cells where they are needed. By synthesizing a nanoparticle that releases its siRNA cargo only after it enters targeted cells, Dr. Tariq M. Rana and colleagues showed in mice that they could deliver drugs that silenced the genes they wanted.

"Our study describes a strategy to reduce toxic effects of nanoparticles, and deliver a cargo to its target," said Dr. Rana, whose paper, "In Vivo Delivery of RNAi by Reducible Interfering Nanoparticles (iNOPs)," also included contributions from researchers at the University of Massachusetts Medical School and the University of California at San Diego. "We've found a way to release the siRNA compounds, so it can be more effective where it's needed," Dr. Rana said.

In their experiment, the team synthesized what they call interfering nanoparticles, or iNOPs, made from repetitively branched molecules of a small natural polymer called poly-L-lysine. The iNOPs were specially designed with positively charged residues connected by disulfide bonds and these iNOPS assemble into a complex with negatively charged siRNA molecules. It's the bonds that ensure that the siRNA molecules remain with the nanoparticle, named iNOP-7DS. However, once inside targeted cells, a naturally occurring and abundant antioxidant called glutathione breaks the bond, releasing the siRNA molecules. In their experiment, Dr. Rana and colleagues showed in the lab that iNOP-7DS is reducible that is, the disulfide bonds holding the siRNA molecules can be broken.

They next showed that iNOP-7DS can be delivered effectively inside cultured murine liver cells, where the siRNA molecules silenced a gene called ApoB. This gene has been notoriously difficult to regulate in liver cells with small molecule drugs; high levels of the protein that ApoB encodes can lead to plaques that cause vascular disease.

Dr. Rana's lab further showed in tests that their nanoparticle remained stable in serum, suggesting that it is not degraded in the bloodstream. Finally, the researchers showed in tests with mice that their nanoparticle iNOP-7DS can be delivered effectively to the liver, spleen, and lung; and it suppressed the level of messenger RNA involved in the expression of the ApoB gene. In their in vivo experiment, they found that extremely small doses of siRNA were effective.

The next step, Dr. Rana said, is to increase the efficacy of iNOP-7DS in other in vivo experiments. "We would like to target not only ApoB, but cancer causing genes as well and in other tissues. That is the next goal." By marshaling the naturally occurring phenomenon of RNA interference, scientists are developing new ways to silence errant gene expression involved in illnesses. The nanoparticles developed by Dr. Rana and colleagues offer a potential new strategy for delivering this powerful therapeutic approach.


'/>"/>

Contact: Deborah Robison
drobison@sanfordburnham.org
407-615-0072
Sanford-Burnham Medical Research Institute
Source:Eurekalert

Related medicine news :

1. Sanford-Burnham collaborates with 5 Florida-based research organizations
2. Sanford-Burnhams Erkki Ruoslahti named to Thomson Reuters Nobel Prize watch list
3. Researchers investigate mechanism of Alzheimers therapy
4. Researchers pinpoint sources of fibrosis-promoting cells that ravage organs
5. Researchers use immunocytochemistry to determine ALK status
6. Researchers find 2 new methods to determine ALK status
7. CWRU researchers trace inner-city womens health issues to childhood traumas
8. Penn Medicine researchers discover link between fear and sound perception
9. UCI researchers awarded $2.27 million to create novel diabetes treatments
10. MS researchers determine that brain reserve independently protects against cognitive decline in MS
11. Notre Dame and Harper researchers developing novel method to test for HPV and oral cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2017)... ... July 25, 2017 , ... Centurion Service Group ... Regional Account Manager for the Northeast and Florida regions. In this role, Jennifer ... obsolete medical assets. , Jennifer joins Centurion with a wealth of knowledge and ...
(Date:7/25/2017)... Texas (PRWEB) , ... July 25, 2017 , ... ... fastest growing ATM provider in the United States, today announced its partnership with ... financial institutions. , The foundation of the solution lies within Hyosung’s superior ...
(Date:7/24/2017)... ... July 24, 2017 , ... Engineers at the University of Maryland have ... same kind of electrical energy that the body uses. , In ordinary batteries ... flow of electrons out of the battery is generated by moving positive ions from ...
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... ... the federal Substance Abuse and Mental Health Services Administration’s (SAMHSA) State Targeted Response ... California Department of Health Care Services, will facilitate the development of a hub ...
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... Every year, ... invigorating and educational conference, InstructureCon. Each annual event is coupled with a dynamic theme ... with a James Bond theme, Mission: InstructureCon 0017. , To extend their partnership ...
Breaking Medicine News(10 mins):
(Date:7/13/2017)... 13, 2017 RK Logistics Group, Inc. was awarded ... for its Fremont, CA headquarters facility ... Tri-Valley and San Jose for hi-tech, ... Fremont , with its Fremont Innovation District, is excited ... a powerful resource to the hundreds of biotech, pharma and ...
(Date:7/12/2017)... ANGELES , July 12, 2017 CarpalAID is a ... drugs, braces or surgery. Carpal tunnel syndrome affects more ... syndrome at twice the rate of men. The common methods of ... or mobilization with uncomfortable hand braces or gloves. ... CarpalAID is a clear ...
(Date:7/11/2017)... , July 11, 2017 Zymo Research Corp., also known ... that can quantify biological aging in a precise manner using the myDNAge ... Steve Horvath , a professor of human genetics and biostatistics at the ... School of Public Health , Zymo Research,s proprietary DNAge ™ technology ... ...
Breaking Medicine Technology: